HLS ASX: Pathology group Healius is restructuring management and cutting costs in its largest business, as UBS presses on with strategic review

  • 📰 FinancialReview
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 90%

대한민국 뉴스 뉴스

대한민국 최근 뉴스,대한민국 헤드 라인

Australia’s No.2 pathology group is cutting costs in a restructure to try to turn around a profit slump, as UBS pushes on with a strategic review.

Two top executives in the group’s Queensland pathology business QML have departed in the restructure outlined in an internal email on March 27 from the boss of the Healius Pathology division, Jan Van Rooyen.

Healius, formerly known as Primary Health Care, replaced its chief executive, Maxine Jaquet, in early March after just 12 months in the job following a profit plunge and $2 billion in sharemarket value disappearing. A revival in the financial performance of the pathology division is crucial for Healius. Mr Van Rooyen was hired to run the division after having been the CEO of AMPATH in South Africa for almost 20 years, which he built into a national business after integrating several smaller operations.

이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 2. in KR
 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.

대한민국 최근 뉴스, 대한민국 헤드 라인